A Study to Evaluate IMGN632 with Venetoclax and/or Azacitidine to Treat Patients with CD123-Positive Acute Myeloid Leukemia


About this study

The purpose of this study is is to determine the safety and tolerability of IMGN632 and assess the antileukemia activity of IMGN632 when administered in combination with azacitidine and/or venetoclax in patients with relapsed and frontline CD123-positive AML, and antileukemia activity of IMGN632 when administered as monotherapy in patients with MRD+ AML after frontline treatment.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Patient must be ≥ 18 years of age.
  • Patients must have confirmed diagnosis of AML (excluding acute promyelocytic leukemia) based on World Health Organization classification (Arber 2016).
  • Disease characteristics and allowable prior therapy:
    • Patients must be evaluated for any available standard of care therapies (including induction, consolidation chemotherapy and/or transplant) and, in the opinion of the treating physician, be deemed appropriate for this experimental therapy;
    • Treatment-naïve (untreated) patients will be allowed in the Expansion Phase for Regimen C (Triplet) (IMGN632 + azacitidine + venetoclax). No prior treatments with hypomethylating agents (HMAs) for MDS are allowed;
    • Patients must have CD123-positive AML as confirmed by local flow cytometry (or immunohistochemistry [IHC]);
    • Patients may have received prior CD123-targeted therapies, except IMGN632, as long as CD123 remains detectable during screening;
    • Relapsed or refractory CD123-positive AML patients will be allowed to enroll in the Escalation Phase of Regimens A, B, and C (Triplet) (IMGN632 + azacitidine, venetoclax, or azacitidine + venetoclax, respectively) and relapsed CD123-positive AML patients will be allowed to enroll the Expansion Phase of Regimens A-C;
    • Note: Patients may also have received up to 2 prior lines of therapy; e.g., frontline treatment (induction, consolidation [including transplant], and maintenance) and 1 salvage regimen;
    • Patients enrolling in Regimen D must be in CR (CR/CRh/CRp/CRi) and be MRD+ at the time of screening, confirmed by central laboratory testing. Patients may have no more than 2 prior lines of therapy (which may include stem cell transplant); i.e., frontline or first salvage.
    • Note: Fit patients who received intensive treatment (e.g., 3+7, HiDAC, etc.) are eligible for Regimen D Cohort D1. Unfit patients who received non-intensive treatment (e.g., HMA, low dose cytarabine, etc.) are eligible for Regimen D Cohort D2.
  • Eastern Cooperative Oncology Group performance status ≤ 1. If non ambulatory due to a chronic disability, must be Karnofsky performance status ≥ 70.
  • Previous treatment-related toxicities must have resolved to Grade 1 or baseline (excluding alopecia).
  • Total white blood cell count must be less than 25 × 10^9 cells/L. Hydroxyurea may be used to control blood counts before Cycle 1 Day 1, at the discretion of the treating physician, according to institutional practice. During the Escalation Phase in Regimens A-C, hydroxyurea may also be used during Cycle 1.
  • Liver enzymes (AST and ALT) ≤ 3 × the upper limit of normal (ULN).
  • Total bilirubin ≤ 1.5 × the ULN.
  • An estimated glomerular filtration rate (eGFR) of > 30 mL/min/1.73 m^2 or creatinine clearance of > 30 mL/min.
  • Left ventricular ejection fraction (LVEF) ≥ 45% based on locally available assessment, eg, echocardiogram or other modality.
  • Patients with prior autologous or allogeneic bone marrow transplant are eligible. Patients with an allogeneic transplant must meet the following conditions: The transplant must have been performed more than 120 days before the date of dosing on this study, the patient must not have active ≥ Grade 2 graft versus host disease (GvHD), or extensive chronic GvHD of any severity, and must be off all immunosuppression for at least 2 weeks prior to first dose of IMGN632.
  • Voluntary written informed consent before performance of any study-related procedure not part of normal medical care.
  • Women of childbearing potential (WCBP), defined as sexually mature women who have not undergone surgical sterilization or who have not been naturally postmenopausal for at least 12 consecutive months (i.e., who have had menses any time in the preceding 12 consecutive months), must agree to use acceptable contraceptive methods while on study drug and for at least 7 months after the last dose of IMGN632.
  • WCBP must have a negative pregnancy test within 3 days before the first dose of study drug.
  • Male patients who are able to father children must agree to use acceptable methods of contraception throughout the study and for at least 4 months after the last dose of IMGN632.
  • Patients with prior malignancy are eligible; however, the patient must be in remission from the prior malignancy and have completed all systemic chemotherapy and radiotherapy for the prior malignancy at least 6 months before enrollment, and all treatment-related toxicities must have resolved to Grade 1 or less.
  • Note: patients with prostate cancer or breast cancer on adjuvant hormonal therapy are eligible.
  • Note: patients with tumors with a negligible risk for metastasis or death (eg, adequately controlled basal cell carcinoma or squamous cell carcinoma of the skin, or carcinoma in situ of the cervix or breast) are eligible.

Exclusion Criteria:

  • Patients who have received any anticancer therapy, including investigational agents, within 14 days (or within 28 days for checkpoint inhibitors) before drug administration on this study (hydroxyurea is allowed before beginning study treatment). Patients must have recovered to baseline from all acute toxicity from this prior therapy.
  • Patients who have been previously treated with IMGN632. Patients with myeloproliferative neoplasm-related secondary AML are excluded from the Dose Expansion Phase of the study.
  • Patients with active central nervous system (CNS) AML will be excluded. A lumbar puncture does not need to be performed unless there is clinical suspicion of CNS involvement per investigator judgement. Concurrent therapy for CNS prophylaxis or continuation of therapy for controlled CNS AML is allowed with the approval of the sponsor.
  • Patients with a history of sinusoidal obstruction syndrome/venous occlusive disease of the liver.
  • Myocardial infarction within 6 months before enrollment or New York Heart Association Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities before study entry.
  • Clinically relevant active infection including known active hepatitis B or C, HIV infection, or cytomegalovirus or any other known concurrent infectious disease that, in the judgment of the investigator, would make a patient inappropriate for enrollment into this study (testing not required).
  • Patients who have undergone a major surgery within 4 weeks (or longer if not fully recovered) before study enrollment.
  • Serious or poorly controlled medical conditions that could be exacerbated by treatment or that would seriously compromise safety assessment or compliance with the protocol, in the judgment of the investigator.
  • Women who are pregnant or breastfeeding.
  • Prior known hypersensitivity reactions to monoclonal antibodies (≥ Grade 3).
  • Prior known hypersensitivity reactions to study drugs and/or any of their excipients.
  • Patients who have a history of allergy to IMGN632 (or any of its excipients), azacitidine, or venetoclax.

Eligibility last updated 11/28/22. Questions regarding updates should be directed to the study team contact. 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Kebede Begna, M.D.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information


Publications are currently not available

Mayo Clinic Footer